Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 in Alcoholic Compensated Cirrhosis With CSPH
CTR20220197Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avenciguat in alcoholic cirrhosis, Portal Hypertension (PH), sponsored by Boehringer Ingelheim. Started Feb 2022; status: terminated.
02
Drugs
avenciguat
03
Conditions
alcoholic cirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on CTR20220197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220197.